Evidence map›Paper›PMID 32561362›Full record

ArticleJournal of biotechnology2020

The covalent SNAP tag for protein display quantification and low-pH protein engineering.

Wei Jin, Bharat Madan, Brooklyn K Mussman, Amen T Hailemariam, Ahmed S Fahad, Jacy R Wolfe, Young Do Kwon, Baoshan Zhang, Lawrence Shapiro, Peter D Kwong and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Wei JinDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, USA.
Bharat MadanDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, USA.
Brooklyn K MussmanDepartment of Chemical & Petroleum Engineering, The University of Kansas, Lawrence, Kansas, USA.
Amen T HailemariamDepartment of Biochemistry, The University of Kansas, Lawrence, Kansas, USA.
Ahmed S FahadDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, USA.
Jacy R WolfeDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, USA.
Young Do KwonVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
Baoshan ZhangVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
Lawrence ShapiroVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA; Department of Biochemistry & Molecular Biophysics, Columbia University, New York, New York, USA; Zuckerman Institute, Columbia University, New York, New York, USA.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA; Department of Biochemistry & Molecular Biophysics, Columbia University, New York, New York, USA.
Brandon J DeKoskyDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, USA; Department of Chemical & Petroleum Engineering, The University of Kansas, Lawrence, Kansas, USA; Kansas Vaccine Institute, The University of Kansas, Lawrence, Kansas, USA. Electronic address: dekosky@ku.edu.
University of Kansas · USNational Institute of Allergy and Infectious Diseases · USColumbia University · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Neutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6M
Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
Understanding the mechanobiology of stem cells in a microengineered 3D cardiac tissue environment with cardiomyopathyP20GM103638 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LUNTE, SUSAN M · 2012 to 2021
$22.1M
The influence of evolutionary landscapes on protective antibody developmentR01AI141452 · NIAID · UNIVERSITY OF COLORADO · PI WHITEHEAD, TIMOTHY ANDREW · 2019 to 2023
$2.8M
Comprehensive analysis of human adaptive immune receptors to elucidate correlates of Epstein-Barr virus disease suppressionDP5OD023118 · OD · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES · 2016 to 2022
$2.2M
NCI NIH HHS 75N91019D00024NIAID NIH HHS R01 AI141452NIGMS NIH HHS P20 GM103638NIGMS NIH HHS P20 GM113117NIH HHS DP5 OD023118
6 · The paper itself

Abstract

Yeast display has become an important tool for modern biotechnology with many advantages for eukaryotic protein engineering. Antibody-based peptide interactions are often used to quantify yeast surface expression (e.g., by fusing a target protein to a FLAG, Myc, polyhistidine, or other peptide tag). However, antibody-antigen interactions require high stability for accurate quantification, and conventional tag systems based on such interactions may not be compatible with a low pH environment. In this study, a SNAP tag was introduced to a yeast display platform to circumvent disadvantages of conventional antibody display tags at low pH. SNAP forms a covalent bond with its small-molecule substrate, enabling precise and pH-independent protein display tagging. We compared the SNAP tag to conventional antibody-based peptide fusion and to direct fluorescent domain fusion using antibody fragment crystallizable (Fc) gene libraries as a case study in low pH protein engineering. Our results demonstrated that covalent SNAP tags can effectively quantify protein-surface expression at low pH, enabling the enrichment of Fc variants with increased affinity at pH 6.0 to the neonatal Fc receptor (FcRn). Incorporation of a covalent SNAP tag thus overcomes disadvantages of conventional antibody-based expression tags and enables protein-engineering applications outside of physiological pH.

Indexed as

Recombinant Fusion ProteinsCell Surface Display TechniquesHistocompatibility Antigens Class IHumansHydrogen-Ion ConcentrationImmunoglobulin Fc FragmentsReceptors, FcYeastsFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin Fc FragmentsReceptors, FcRecombinant Fusion ProteinsFc-FcRnLow pH protein engineeringSNAPYeast display

Identifiers

PMID32561362
PMCPMC7434562
OpenAlexW3035714708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.